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Recent studies point out at the role of apoptosis
disturbances in the development of systemic sclero-
sis (SSc).
The aim of our study was to examine caspase 1 and
sFas serum levels in scleroderma patients and corre-
late the obtained results with skin involvement and
internal organ changes.
We studied 29 patients (14 with limited and 15 with
diffuse SSc). The extension of skin involvement was
measured using Total Skin Score (TSS). Internal organ
involvement was assessed by specialist procedures.
Serum caspase 1 and sFas levels were measured by
enzyme-linked immunosorbent assay.
We found correlation between sFas serum level and
duration of Raynaud’s phenomenon and TSS; caspase
1 serum level correlated only with TSS. Correlations
between caspase 1 and lung dysfunction and sFas
levels with joint and bone involvement in SSc
patients were also observed.
The obtained results revealed that disturbances of
apoptosis might play a role in SSc pathogenesis.
Caspase 1 and sFas serum levels correlate with the
skin involvement severity, lung dysfunction, joint
and bone changes.
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Introduction
Apoptosis, genetically programmed cell death, plays
an important role in embryonogenesis, reparation
and regeneration processes.
1 The disturbance of
apoptosis in lymphocytes including autoreactive
clones could induce autoantibody production.
2,3
There are some literature data suggesting that abnor-
mal regulation of apoptosis might be one of the
important factors in pathogenesis of systemic lupus
erythematosus, rheumatoid arthritis and systemic
sclerosis (SSc).
46
Cysteine-aspartic acid-specific proteases (caspases)
appear to have important roles in apoptotic execu-
tion.
7,8 Until now, three families of those enzymes,
playing different roles in the cells, have been
demonstrated: caspases regulating pro-inflammatory
cytokine maturation, initiating caspases, and execu-
tive caspases.
It is widely accepted that proteolytic enzymes
destroy structural and enzymatic cell proteins; how-
ever, their precise role has not been elucidated.
Caspase 1 is also called interleukin-1b converting
enzyme, pro-interleukin-18 and phospholipase A2
converting enzyme.
9,10 Literature data indicate that
the aforementioned proteolytic enzyme, however, is
not indispensable in apoptosis, and plays an impor-
tant role in cytokine release and inflammation devel-
opment.
9,10 All the caspase producing cells, or at least
the majority of them, have to have strong mechan-
isms preventing activation of these enzymes.
11
Although apoptosis is based on genetically pro-
grammed changes in cells, there are some apoptosis
regulating factors in the organisms. Some proteins
from the tumour necrosis factor family such as myc
and Fas (called also APO-1 or CD95) can trigger
apoptosis.
12 Several factors could also inhibit pro-
grammed cell death: oncogen bcl-2, excessive
amounts of soluble tumour necrosis factor-alpha
receptor and antioxidants.
7
In the group of chronic connective tissue diseases,
systemic sclerosis is characterized by dysregulation of
the immune system and excessive accumulation of
extracellular matrix in the skin and various internal
organs.
13 It seems that imbalance between pro-
apoptotic and anti-apoptotic factors could be respon-
sible not only for immunological disturbances and
inflammation, but for internal organ involvement in
the course of systemic sclerosis as well, just like in
systemic lupus erythematosus.
4
The aim of our study was to perform measure-
ments of caspase 1 and sFas serum levels in 29
scleroderma patients in comparison with the control
group and their correlation with duration of Ray-
naud’s phenomenon, duration of skin involvement
and its extent together with internal organ changes.
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339Materials and methods
Our study involved 29 SSc patients, 23 women and
six men, age range 16/69 years. In our group, 15
patients presented the diffuse form (dSSc) (mean age,
45.49 /12.1 years) and 14 patients limited SSc (lSSc)
(mean age, 51.69 /12.9 years). All the patients were
diagnosed according to ARA criteria.
14 Because of the
rapid disease progression, all the dSSc patients were
on immunosuppressive regimen (50 mg cyclopho-
sphamide daily and 20 mg prednison daily).
Duration of Raynaud’s phenomenon and skin
sclerosis were evaluated in all the patients. The
degree of skin sclerosis was assessed using the Total
Skin Score according to Kahaleh et al. (0/66
points).
15
Four internal organs, the oesophagus, the cardio-
vascular system, the joint and bone system, and the
lung, were evaluated by six specific tests: (1)
oesophagal scintigraphy, (2) electrocardiography,
(3) Doppler echocardiography, (4) X-ray feet and
hand bone, (5) X-ray chest, and (6) lung spirometry.
The letter was expressed in percentages of the
required value: forced vital capacity (FVC), forced
expiratory volume in 1 sec (FEV1) and the ratio FEV1/
FVC. Restrictive disturbances of the lungs were
diagnosed when FVC was below 80% of the desired
value, while the value of the ratio FEV1/FVC was
elevated or within the normal range. Obstructing
lesions were diagnosed when the value of FEV1 was
reduced, and mixed lesions when the reduction in
the predicted values of both FVC and FEV1 were
similar.
16 Those parameters were not scored.
Blood was collected in the morning into the
pyrogen-free tubes and stored at /208C until further
evaluated. Caspase 1 levels were measured in 17
patients (eight with dSSc and nine with lSSc) and sFas
in 29 patients (15 with dSSc and 14 with lSSc). The
control group consisted of 10 healthy persons (nine
women and one man, aged 25/64 years; mean age,
46.39 /13.2 years).
Caspase 1 and sFas serum levels were evaluated by
enzyme-linked immunoassay (ELISA) technique
(Quantikine R&D Systems Inc., Minneapolis, USA).
The detection sensitivity of caspase 1 ranged between
0.22 and 1.24 pg/ml, and the minimum detectable
dose of sFas is typically less than 20 pg/ml.
All patients and individuals from the control group
gave their informed consent to participate in our
study according to the Bioethic Committee of Medical
University of Lodz requirements.
Statistical analysis
The obtained results were expressed as mean,
maximum, minimum, and median values together
with standard deviation. Numerical variables distribu-
tion was assessed by Shapiro/Wilk test. Mann/
Whitney, Cochran/Cox and two independent sample
tests were employed for comparison of mean or
median values. Correlation between numerical values
was evaluated by Spearman range correlation coeffi-
cient, r. pB/0.05 was considered statistically signifi-
cant.
Results
Characteristics of the patients are presented in
Table 1. Table 2 presents abnormalities and changes
in internal organs observed in the examined group of
patients.
It was demonstrated that mean caspase 1 levels
were lower in SSc patients than in the control group
(61.69 /76.4 pg/ml and 212.49 /246.2 pg/ml, respec-
tively, at p/0.005). It was also observed that dSSc
patients demonstrated higher caspase 1 levels than
lSSc ones (89.79 /87.1 pg/ml and 36.59 /59.4 pg/ml,
respectively, at p/0.1). Mean serum sFas levels were
higher in the patient group than in the healthy
controls (3098.39 /624.4 pg/ml and 1080.19 /429.5
pg/ml, respectively, at p/0.00005). What is more,
dSSc patients had higher sFas serum levels than the
lSSc group (3239.39 /483.2 pg/ml and 2947.29 /735.3
pg/ml, respectively) (Table 3).
Statistical analysis with the Spearman range corre-
lation coefficient demonstrated statistically signifi-
cant, negative correlations between duration of
Raynaud’s phenomenon and sFas serum levels in
systemic sclerosis patients as a whole group (r/
/0.549, p/0.002) and limited SSc patients (r/
/0.672, p/0.009) (Table 4).
We analysed the relationship between serum con-
centrations of both parameters and extensiveness of
skin involvement. We found positive correlations
Table 1. Characteristics of the examined patients
Systemic sclerosis
patients
Limited systemic sclerosis
patients
Diffuse systemic sclerosis
patients
Raynaud’s phenomenon duration (years) 11.39 /9.7* 17.09 /11.4* 6.19 /2.8*
Disease duration (years) 4.79 /4.1* 6.49 /4.8* 3.19 /2.6*
Total Skin Score (points) 29.99 /13.9 17.79 /4.6* 41.39 /9.0*
* Differences statistically significant at pB/0.05.
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systemic sclerosis patients as a whole group and Total
Skin Score. In contrast, we observed negative corre-
lation between caspase 1 (r//0.711, p/0.04) and
sFas (r//0.097) serum levels and Total Skin Score
in the diffuse SSc patient subgroup (Table 4).
We also analysed caspase 1 and sFas serum levels
in comparison with organ involvement in systemic
sclerosis patients. We observed significantly lower
caspase 1 levels in lSSc patients who had more
internal organs involved (r//0.709, p/0.03).
Statistical analysis showed that the mean value of
caspase 1 level was statistically significantly lower in
limited SSc patients with pulmonary dysfunction than
in those without these disturbances (p/0.05). In the
same group of systemic sclerosis patients, mean value
of sFas was higher in the patients with joint and bone
changes than without them (p/0.02).
Table 2. Abnormalities in the internal organs observed in the examined group of systemic sclerosis patients
Type of examination* Result of the
examination
Type of systemic sclerosis
Systemic sclerosis
(total) (n/29)
Limited systemic
sclerosis (n/14)
Diffuse systemic
sclerosis (n/15)
Oesophagus scyntigraphy Normal 7 3 4
Abnormal 22 11 11
Heart (electrocardiography and
Doppler echocardiography)
Normal 16 8 8
Abnormal 13 6 7
X-ray hand and feet bone Normal 8 3 5
Abnormal 21 11 10
X-ray chest Normal 18 10 8
Abnormal 11 4 7
Spirometry Normal 11 6 5
Abnormal 18 8 10
* Oesophagal scyntigragraphy abnormalities: retarded passage in the lower and/or central part of the oesophagus. Cardio-vascular
abnormalities: tendency to tachyarrhythmias, lower potentials of different parameters describing variability of cardiac rythmus or conduction
system abnormalities, ventricular arrhythmia, silent ischaemic episodes, diastolic left ventricular disturbances, valvular lesions. Changes in
osteo-articular system: juxta-articular demineralization, joint space narrowing in digitals. X-ray chest changes: symmetrical fibrosis of the lung
base and ‘honey-comb’ picture. Spirometry: lung function disturbances of restrictive, obstructive or mixed type.
Table 3. Serum concentration of caspase 1 and sFas in patients with systemic sclerosis and control group
Caspase 1 (pg/ml) sFas (pg/ml)
Systemic
sclerosis
(n/17)
Limited
systemic
sclerosis
(n/9)
Diffuse
systemic
sclerosis
(n/8)
Control group
(n/10)
Systemic
sclerosis
(n/29)
Limited
systemic
sclerosis
(n/14)
Diffuse
systemic
sclerosis
(n/15)
Control group
(n/10)
Mean9 /standard
deviation
61.6*9 /76.4 36.5*9 /59.4 89.7*9 /87.1 212.49 /246.2 3098.3*9 /624.4 2947.2*9 /735.3 3239.3*9 /483.2 1080.19 /429.5
Median 21.7 7.0 54.1 100.5 3064.0 2822.1 3073.4 965.1
Range 0.0/219.7 0.0/159.4 3.7/219.7 22.6/727.0 1663.3/4435.8 1663.3/4435.8 2513.8/4417.4 594.4/1984.9
* Statistically significant at pB/0.05, difference between mean or median value and the control group.
Table 4. Correlation between caspase 1 and sFas serum levels and duration of Raynaud’s phenomenon, duration of skin
involvement, Total Skin Score and number of internal organs involved in 29 examined patients with systemic sclerosis
Caspase 1 sFas
Systemic sclero-
sis (n/17)
Limited systemic
sclerosis (n/9)
Diffuse systemic
sclerosis (n/8)
Systemic sclero-
sis (n/29)
Limited systemic
sclerosis (n/14)
Diffuse systemic
sclerosis (n/15)
Duration of Raynaud’s phenomenon
r 0.156 0.301 0.467 /0.549* /0.672* 0.141
p 0.5 0.4 0.2 0.002 0.009 0.6
Duration of skin involvement
r 0.082 0.026 0.147 /0.288 /0.370 0.261
p 0.8 0.9 0.7 0.1 0.2 0.3
Total Skin Score
r 0.181 /0.203 /0.711* 0.365** 0.279 /0.097
p 0.5 0.6 0.04 0.05 0.3 0.7
Number of internal organs involved
r 0.028 /0.709* 0.422 0.093 /0.038 0.225
p 0.9 0.03 0.3 0.6 0.9 0.4
* Statistically significant.
** P/0.05.
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Literature data has reported disturbances in apoptosis
in the development of systemic sclerosis.
17 Szpringer
and Lutnicki pointed at considerable inflammatory
changes of blood vessels and fibroblast proliferation
that could result from either increased production of
growth factors or decreased sensitivity of those cells
towards apoptosis inducing factors.
17
Some experimental data suggest that serum cata-
bolic enzymes may influence apoptosis extensivity. It
is postulated that inflammatory processes in scler-
oderma may lead to increased collagen deposition in
the tissues. It was demonstrated that caspase 1,
caspase 4, caspase 5 and caspase 11 can trigger
inflammatory processes.
18 To the best of our knowl-
edge, there is no literature data on serum caspase
level evaluation in systemic sclerosis patients. Our
study demonstrated higher mean caspase 1 serum
levels in the control group in comparison with
systemic sclerosis patients. This observation could
suggest that lower serum levels of this protease
correlated with apoptosis inhibition in systemic
sclerosis patients.
Until now, evaluation of skin lesion severity has
been one of the very important parameters of disease
activity. We found a strong, statistically significant
correlation in diffuse SSc patients between more
extensive skin involvement and lower caspase 1
levels. Perhaps this data could account for one of
the factors responsible for fibrosis development
because more severe apoptosis disturbances are
observed in this group in comparison with less severe
cases.
Teraki and Shiohara pointed out at the important
role of caspase 1 in Fas-triggered apoptotic pro-
cesses.
7 Caspase 1 activates effector protease caspase
3 in cysteine protease cascade. Caspase 1 plays an
important role in cytokine release and induction of
the inflammatory reaction.
19 It is suggested that lower
caspase 1 levels can inhibit apoptosis in the initial
stages of systemic sclerosis development, which in
turn can activate T lymphocytes and B lymphocytes.
Our data showed correlation between lower caspase
1 serum levels in patients with some internal organs
involved. The statistically significant correlation was
found only in limited SSc patients with pulmonary
dysfunction diagnosed on spirometry. We had as-
sumed that our treatment regimens did not influence
caspase 1 levels. Both in patients on either immuno-
suppressive treatment or vasodilatators and vitamin
E, caspase 1 levels were lower than in the control
group.
Literature data point out the importance of sFas in
apoptosis in the course of autoimmunological dis-
orders.
20,21 Higher sFas serum levels were demon-
strated in patients with rheumatoid arthritis, systemic
lupus erythematosus, mixed connective tissue dis-
ease, dermatomyositis-polymyositis and silicosis as
well as in scleroderma, when comparing with the
control groups.
3,21
The results obtained by us also showed statistically
significant higher sFas serum levels in scleroderma
patients in comparison with the control group. Those
differences seem to depend on the clinical presenta-
tion. Serum sFas levels were higher in the dSSc
subgroup than in the lSSc one. We found strong
correlations between shorter duration of Raynaud’s
phenomenon and higher sFas serum concentration.
Soluble Fas levels also correlated with skin involve-
ment severity. What is more, patients with joint and
bone changes also presented increased sFas serum
levels.
It could be assumed that, just like in systemic lupus
erythematosus, also in scleroderma higher sFas
serum levels may be regarded as a manifestation of
some systemic changes.
3 The observed results are in
agreement with the literature data demonstrating
importance of sFas in apoptosis triggering in the
course of autoimmune diseases.
22,23
Increased sFas serum levels in systemic sclerosis
patients may protect autoreactive T lymphocytes
against apoptosis induced by the Fas ligand system.
21
Fas stimulation prevents intracellular calcium ions
entrance, which is obligatory for lymphocyte T
proliferation, differentiation and cytokine produc-
tion.
4 Wetzig et al. demonstrated increased sFas
serum levels in the group of 30 scleroderma patients
in comparison with the controls.
24 There were no
significant differences in this protein serum level
between lSSc and dSSc patients. This research group
concluded that sFas serum levels in scleroderma
patients might be only a clinical marker of auto-
immune disturbances in the course of this disease but
not a reliable parameter of inflammatory process
activity.
Our results showed that imbalance between cas-
pase 1 and sFas serum levels could exert an inhibitory
effect on apoptosis in patients with systemic sclerosis.
Serum levels of caspase 1 and sFas correlated with
skin involvement, sFas levels with bone and joint
changes, and caspase 1 with pulmonary dysfunction.
ACKNOWLEDGEMENTS. This work was supported by the Medical Uni-
versity of Lodz research grant no. 502-11-697.
References
1. Wyllie AK, Kerr JFR, Currie AR. Cell death: the signiﬁcance of apoptosis.
Int Rev Cytol 1980; 68: 251/306.
2. Le Roy EC. Increased collagen synthesis by scleroderma ﬁbroblasts in
vitro. J Clin Invest 1974; 54: 880/809.
3. Ueki A, Sozaki Y, Tomokuni A, et al. Intramolecular epitope spreading
among anti-caspase-8 autoantibodies in patients with silicosis, systemic
sclerosis and systemic lupus erythemstosus, as well in healthy indivi-
duals. Clin Exp Immunol 2002; 129: 556/561.
B. Dziankowska-Bartkowiak et al.
342 Mediators of Inflammation Vol 12  20034. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H.
Soluble Fas (APO-1, CD95) and soluble Fas Ligand in rheumatic
diseases. Arthritis Rheum 1997; 40: 1126/1129.
5. Al-Maini MH, Mountz JD, Al-Mohri HA, et al. Serum levels of soluble Fas
correlate with indices of organ damage in systemic lupus erythematosus.
Lupus 2000; 9:1 3 2/139.
6. Waszczykowska E, Sysa-Jedrzejowska A, Dziankowska-Bartkowiak B,
Narbutt J, Pagounis C, Majewski S. Apoptosis in the skin of patients with
autoimmune connective tissue disorders. Centr Eur J Immunol 2001; 26:
53/58.
7. Teraki Y, Shiohara T. Apoptosis and the skin. Eur J Dermatol 1999; 9:
413/426.
8. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis.
Cell 1997; 91: 443/446.
9. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric
cysteine protease is required for interleukin-1 beta processing in
monocytes. Nature 1992; 356: 768/774.
10. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Casapase 1-
independent IL-1b release and inﬂammation induced by the apoptosis
inducer Fas ligand. Nat Med 1998; 4: 1287/1292.
11. Wyllie AH. Apoptosis: an overview. Br Med Bull 1997; 53: 451/465.
12. Cohen JJ. Overview:mechanisms of apoptosis. Immunol Today 1993;
14:1 2 6/130.
13. Bunn CC, Black CM. Systemic sclerosis: an autoantibody mosaic. Clin
Exp Immunol 1999; 117: 207/208.
14. Subcommittee for scleroderma Criteria of the American Rheumatism
Association Diagnostic and Therapeutic Criteria Committee. Preliminary
criteria for the classiﬁcation of systemic sclerosis (scleroderma). Arthritis
Rheum 1980; 23:5 8 1/590.
15. Kahaleh MB, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy
EC. A modiﬁed scleroderma skin score method. Clin Exp Rheumatol
1986; 4:3 6 7/369.
16. Martinez FJ. Badania czynnosciowe ukladu oddechowego. In: Khan MG,
Lynch JP III (eds). Choroby pluc. Diagnostyka I terapia. Urban and
Partner, 1st edition (in Polish). 2000: 103/120.
17. Szpringer E, Lutnicki K. Znaczenie apoptozy w wybranych chorobach w
dermatologii (in Polish). Nowa Medycyna 2002; 116:2 4/32.
18. Zhivotovsky B, Samali A, Gahm A, Orrenius S. Caspase: their intracel-
lular localization and translocation during apoptosis. Cell Death Diff
1999; 8: 644/651.
19. Wang S, Miura M, Yung YK, Zhu H, Li E, Yuan J. Murine caspase-11, an
ICE-interacting protease, is essential for the activation of ICE. Cell 1998;
92: 501/509.
20. Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease: a problem of
defective apoptosis. Arthritis Rheum 1994; 37: 1415/1420.
21. Bianchi T, Bardazzi F, Patrizi A. Soluble Fas levels in patients with
systemic sclerosis. Arch Dermatol Res 2000; 292:5 2 2/523.
22. Tomokuni A, Otsuki T, Isozaki Y, et al. Serum levels of soluble Fas
ligand in patients with silicosis. Clin Exp Immunol 1999; 118:4 4 1/444.
23. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G.
Endothelial cell apoptosis is primary pathogenic event underlying skin
lesions in avian and human scleroderma. J Clin Invest 1996; 98:7 8 5 /
792.
24. Wetzig T, Petri JB, Mittag M, Haustein UF. Serum levels of soluble Fas/
APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res
1998; 290: 187/190.
Received 26 August 2003
Accepted 18 September 2003
Caspase 1 and sFas serum levels in systemic sclerosis patients
Mediators of Inflammation Vol 12  2003 343